BSA conjugates bearing multiple copies of the basic domain of HIV-1 Tat: Prototype for the development of multitarget inhibitors of extracellular Tat

Antiviral Research

Volumn 87, Issue 1, 2010, Pages 30-39

  Bugatti, Antonella ^a   Chiodelli, Paola ^a   Rosenbluh, Joseph ^b   Loyter, Abraham ^b   Rusnati, Marco ^a  

^a UNIVERSITY OF BRESCIA   (Italy)

^b HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

AIDS; Angiogenesis; Endothelial cells; Heparan sulfate proteoglycans; HIV; Integrins; Transactivation; Vascular endothelial growth factor receptor 2

Indexed keywords

BOVINE SERUM ALBUMIN; HEPARIN; PROTEOHEPARAN SULFATE; TRANSACTIVATOR PROTEIN; VASCULOTROPIN RECEPTOR 2; VITRONECTIN RECEPTOR;

ARTICLE; CELL ADHESION; CELL LEVEL; CONTROLLED STUDY; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; INTERNALIZATION; NUCLEAR LOCALIZATION SIGNAL; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DOMAIN; SURFACE PLASMON RESONANCE;

HELA CELLS; HEPARIN; HIV FUSION INHIBITORS; HIV-1; HUMANS; PROTEIN BINDING; SERUM ALBUMIN, BOVINE; SURFACE PLASMON RESONANCE; TAT GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; VIRUS INTERNALIZATION;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 77953545354     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2010.04.004     Document Type: Article

References (63)

1. Albini A., Benelli R., Presta M., Rusnati M., Ziche M., Rubartelli A., Paglialunga G., Bussolino F., Noonan D. HIV-tat protein is a heparin-binding angiogenic growth factor. Oncogene 1996, 12:289-297.
2. Albini A., Soldi R., Giunciuglio D., Giraudo E., Benelli R., Primo L., Noonan D., Salio M., Camussi G., Rockl W., Bussolino F. The angiogenesis induced by HIV-1 tat protein is mediated by the Flk-1/KDR receptor on vascular endothelial cells. Nat. Med. 1996, 2:1371-1375.
3. Albini A., Ferrini S., Benelli R., Sforzini S., Giunciuglio D., Aluigi M.G., Proudfoot A.E., Alouani S., Wells T.N., Mariani G., Rabin R.L., Farber J.M., Noonan D.M. HIV-1 Tat protein mimicry of chemokines. Proc. Natl. Acad. Sci. U.S.A. 1998, 95:13153-13158.
4. Armon-Omer A., Graessmann A., Loyter A. A synthetic peptide bearing the HIV-1 integrase 161-173 amino acid residues mediates active nuclear import and binding to importin alpha: characterization of a functional nuclear localization signal. J. Mol. Biol. 2004, 336:1117-1128.
5. Bobardt M.D., Salmon P., Wang L., Esko J.D., Gabuzda D., Fiala M., Trono D., Van der Schueren B., David G., Gallay P.A. Contribution of proteoglycans to human immunodeficiency virus type 1 brain invasion. J. Virol. 2004, 78:6567-6584.
6. Broder Y.C., Stanhill A., Zakai N., Friedler A., Gilon C., Loyter A. Translocation of NLS-BSA conjugates into nuclei of permeabilized mammalian cells can be supported by protoplast extract. An experimental system for studying plant cytosolic factors involved in nuclear import. FEBS Lett. 1997, 412:535-539.
7. Chang H.C., Samaniego F., Nair B.C., Buonaguro L., Ensoli B. HIV-1 Tat protein exits from cells via a leaderless secretory pathway and binds to extracellular matrix-associated heparan sulfate proteoglycans through its basic region. AIDS 1997, 11:1421-1431.
8. Chauhan A., Tikoo A., Kapur A.K., Singh M. The taming of the cell penetrating domain of the HIV Tat: myths and realities. J. Control Release 2007, 117:148-162.
9. Cullen B.R. Regulation of HIV gene expression. AIDS 1995, 9(Suppl. A):S19-32.
10. Daelemans D., Schols D., Witvrouw M., Pannecouque C., Hatse S., van Dooren S., Hamy F., Klimkait T., De Clercq E., Vandamme A.M. A second target for the peptoid Tat/transactivation response element inhibitor CGP64222: inhibition of human immunodeficiency virus replication by blocking CXC-chemokine receptor 4-mediated virus entry. Mol. Pharmacol. 2000, 57:116-124.
11. Dayton A.I., Sodroski J.G., Rosen C.A., Goh W.C., Haseltine W.A. The trans-activator gene of the human T cell lymphotropic virus type III is required for replication. Cell 1986, 44:941-947.
12. Efthymiadis A., Briggs L.J., Jans D.A. The HIV-1 Tat nuclear localization sequence confers novel nuclear import properties. J. Biol. Chem. 1998, 273:1623-1628.
13. Ensoli B., Buonaguro L., Barillari G., Fiorelli V., Gendelman R., Morgan R.A., Wingfield P., Gallo R.C. Release, uptake, and effects of extracellular human immunodeficiency virus type 1 Tat protein on cell growth and viral transactivation. J. Virol. 1993, 67:277-287.
14. Fisher A.G., Feinberg M.B., Josephs S.F., Harper M.E., Marselle L.M., Reyes G., Gonda M.A., Aldovini A., Debouk C., Gallo R.C., Wong-Staal F. The trans-activator gene of HTLV-III is essential for virus replication. Nature 1986, 320:367-371.
15. Fittipaldi A., Giacca M. Transcellular protein transduction using the Tat protein of HIV-1. Adv. Drug Deliv. Rev. 2005, 57:597-608.
16. Folkman J., Klagsbrun M. Angiogenic factors. Science 1987, 235:442-447.
17. Frankel A.D., Pabo C.O. Cellular uptake of the tat protein from human immunodeficiency virus. Cell 1988, 55:1189-1193.
18. Friedler A., Zakai N., Karni O., Friedler D., Gilon C., Loyter A. Identification of a nuclear transport inhibitory signal (NTIS) in the basic domain of HIV-1 Vif protein. J. Mol. Biol. 1999, 289:431-437.
19. Fulcher A.J., Jans D.A. The HIV-1 Tat transactivator protein: a therapeutic target?. IUBMB Life 2003, 55:669-680.
20. Futaki S., Suzuki T., Ohashi W., Yagami T., Tanaka S., Ueda K., Sugiura Y. Arginine-rich peptides. An abundant source of membrane-permeable peptides having potential as carriers for intracellular protein delivery. J. Biol. Chem. 2001, 276:5836-5840.
21. Gautier V.W., Sheehy N., Duffy M., Hashimoto K., Hall W.W. Direct interaction of the human I-mfa domain-containing protein, HIC, with HIV-1 Tat results in cytoplasmic sequestration and control of Tat activity. Proc. Natl. Acad. Sci. U.S.A. 2005, 102:16362-16367.
22. Giacca M. The HIV-1 Tat protein: a multifaceted target for novel therapeutic opportunities. Curr. Drug Targets Immune Endocr. Metabol. Disord. 2004, 4:277-285.
23. Goldfarb D.S., Gariépy J., Schoolnik G., Kornberg R.D. Synthetic peptides as nuclear localization signals. Nature 1986, 322:641-644.
24. Goldstein G. HIV-1 Tat protein as a potential AIDS vaccine. Nat. Med. 1996, 2:960-964.
25. Grinspan J.B., Mueller S.N., Levine E.M. Bovine endothelial cells transformed in vitro by benzo(a)pyrene. J. Cell Physiol. 1983, 114:328-338.
26. Hamy F., Felder E.R., Heizmann G., Lazdins J., Aboul-ela F., Varani G., Karn J., Klimkait T. An inhibitor of the Tat/TAR RNA interaction that effectively suppresses HIV-1 replication. Proc. Natl. Acad. Sci. U.S.A. 1997, 94:3548-3553.
27. Hamy F., Gelus N., Zeller M., Lazdins J.L., Bailly C., Klimkait T. Blocking HIV replication by targeting Tat protein. Chem. Biol. 2000, 7:669-676.
28. Hariton-Gazal E., Rosenbluh J., Graessmann A., Gilon C., Loyter A. Direct translocation of histone molecules across cell membranes. J. Cell Sci. 2003, 116:4577-4586.
29. Hodel M.R., Corbett A.H., Hodel A.E. Dissection of a nuclear localization signal. J. Biol. Chem. 2001, 276:1317-1325.
30. Jans D.A., Xiao C.Y., Lam M.H. Nuclear targeting signal recognition: a key control point in nuclear transport?. Bioessays 2000, 22:532-544.
31. Kim C.M., Vogel J., Jay G., Rhim J.S. The HIV tat gene transforms human keratinocytes. Oncogene 1992, 7:1525-1529.
32. Krichevsky A., Rusnati M., Bugatti A., Waigmann E., Shohat S., Loyter A. The fd phage and a peptide derived from its p8 coat protein interact with the HIV-1 Tat-NLS and inhibit its biological functions. Antiviral Res. 2005, 66:67-78.
33. Lauder H., Frost E.E., Hiley C.R., Fan T.P. Quantification of the repair process involved in the repair of a cell monolayer using an in vitro model of mechanical injury. Angiogenesis 1998, 2:67-80.
34. Liang S.H., Clarke M.F. Regulation of p53 localization. Eur. J. Biochem. 2001, 268:2779-2783.
35. Mann D.A., Frankel A.D. Endocytosis and targeting of exogenous HIV-1 Tat protein. EMBO J. 1991, 10:1733-1739.
36. Marchiò S., Alfano M., Primo L., Gramaglia D., Butini L., Gennero L., De Vivo E., Arap W., Giacca M., Pasqualini R., Bussolino F. Cell surface-associated Tat modulates HIV-1 infection and spreading through a specific interaction with gp120 viral envelope protein. Blood 2005, 105:2802-2811.
37. Mulloy B., Linhardt R.J. Order out of complexity-protein structures that interact with heparin. Curr. Opin. Struct. Biol. 2001, 11:623-628.
38. Neufeld G., Cohen T., Gengrinovitch S., Poltorak Z. Vascular endothelial growth factor (VEGF) and its receptors. FASEB J. 1999, 13:9-22.
39. Peterlin B.M., Adams M., Alonso A., Baur A., Ghosh S., Lu X., Luo X. Tat transactivator. Human Retroviruses 1993, 75-100. Oxford University Press, Oxford. B.R. Cullen (Ed.).
40. Ping L.H., Nelson J.A., Hoffman I.F., Schock J., Lamers S.L., Goodman M., Vernazza P., Kazembe P., Maida M., Zimba D., Goodenow M.M., Eron J.J., Fiscus S.A., Cohen M.S., Swanstrom R. Characterization of V3 sequence heterogeneity in subtype C human immunodeficiency virus type 1 isolates from Malawi: underrepresentation of X4 variants. J. Virol. 1999, 73:6271-6281.
41. Richter S.N., Palù G. Inhibitors of HIV-1 Tat-mediated transactivation. Curr. Med. Chem. 2006, 13:1305-1315.
42. Rizzi C., Alfano M., Bugatti A., Camozzi M., Poli G., Rusnati M. Inhibition of intra- and extra-cellular Tat function and HIV expression by pertussis toxin B-oligomer. Eur. J. Immunol. 2004, 34:530-536.
43. Rusnati M., Presta M. HIV-1 Tat protein and endothelium: from protein/cell interaction to AIDS-associated pathologies. Angiogenesis 2002, 5:141-151.
44. Rusnati M., Presta M. HIV-1 Tat protein: a target for the development of anti-AIDS therapies. Drug Fut. 2002, 27:481-493.
45. Rusnati M., Urbinati C. Polysulfated/sulfonated compounds for the development of drugs at the crossroad of viral infection and oncogenesis. Curr. Pharmacol. Des. 2009, 15:2946-2957.
46. Rusnati M., Coltrini D., Oreste P., Zoppetti G., Albini A., Noonan D., d'Adda di Fagagna F., Giacca M., Presta M. Interaction of HIV-1 Tat protein with heparin. Role of the backbone structure, sulfation, and size. J. Biol. Chem. 1997, 272:11313-11320.
47. Rusnati M., Tanghetti E., Dell'Era P., Gualandris A., Presta M. alphavbeta3 integrin mediates the cell-adhesive capacity and biological activity of basic fibroblast growth factor (FGF-2) in cultured endothelial cells. Mol. Biol. Cell 1997, 8:2449-2461.
48. Rusnati M., Tulipano G., Urbinati C., Tanghetti E., Giuliani R., Giacca M., Ciomei M., Corallini A., Presta M. The basic domain in HIV-1 Tat protein as a target for polysulfonated heparin-mimicking extracellular Tat antagonists. J. Biol. Chem. 1998, 273:16027-16037.
49. Rusnati M., Tulipano G., Spillmann D., Tanghetti E., Oreste P., Zoppetti G., Giacca M., Presta M. Multiple interactions of HIV-I Tat protein with size-defined heparin oligosaccharides. J. Biol. Chem. 1999, 274:28198-28205.
50. Rusnati M., Taraboletti G., Urbinati C., Tulipano G., Giuliani R., Molinari-Tosatti M.P., Sennino B., Giacca M., Tyagi M., Albini A., Noonan D., Giavazzi R., Presta M. Thrombospondin-1/HIV-1 tat protein interaction: modulation of the biological activity of extracellular Tat. FASEB J. 2000, 14:1917-1930.
51. Rusnati M., Urbinati C., Caputo A., Possati L., Lortat-Jacob H., Giacca M., Ribatti D., Presta M. Pentosan polysulfate as an inhibitor of extracellular HIV-1 Tat. J. Biol. Chem. 2001, 276:22420-22425.
52. Rusnati M., Urbinati C., Musulin B., Ribatti D., Albini A., Noonan D., Marchisone C., Waltenberger J., Presta M. Activation of endothelial cell mitogen activated protein kinase ERK(1/2) by extracellular HIV-1 Tat protein. Endothelium 2001, 8:65-74.
53. Rusnati M., Oreste P., Zoppetti G., Presta M. Biotechnological engineering of heparin/heparan sulfate: a novel area of multi-target drug discovery. Curr. Pharmacol. Des. 2005, 11:2489-2499.
54. Rusnati M., Vicenzi E., Donalisio M., Oreste P., Landolfo S., Lembo D. Sulfated K5 Escherichia coli polysaccharide derivatives: a novel class of candidate antiviral microbicides. Pharmacol. Ther. 2009, 123:310-322.
55. Schwartz S., Felber B.K., Fenyö E.M., Pavlakis G.N. Env and Vpu proteins of human immunodeficiency virus type 1 are produced from multiple bicistronic mRNAs. J. Virol. 1990, 64:5448-5456.
56. Tyagi M., Rusnati M., Presta M., Giacca M. Internalization of HIV-1 tat requires cell surface heparan sulfate proteoglycans. J. Biol. Chem. 2001, 276:3254-3261.
57. Urbinati C., Bugatti A., Giacca M., Schlaepfer D., Presta M., Rusnati M. alpha(v)beta3-integrin-dependent activation of focal adhesion kinase mediates NF-kappaB activation and motogenic activity by HIV-1 Tat in endothelial cells. J. Cell Sci. 2005, 118:2958-3949.
58. Urbinati C., Mitola S., Tanghetti E., Kumar C., Waltenberger J., Ribatti D., Presta M., Rusnati M. Integrin alphavbeta3 as a target for blocking HIV-1 Tat-induced endothelial cell activation in vitro and angiogenesis in vivo. Arterioscler. Thromb. Vasc. Biol. 2005, 25:2315-2320.
59. Urbinati C., Chiodelli P., Rusnati M. Polyanionic drugs and viral oncogenesis: a novel approach to control infection, tumor-associated inflammation and angiogenesis. Molecules 2008, 13:2758-2785.
60. Urbinati C., Nicoli S., Giacca M., David G., Fiorentini S., Caruso A., Alfano M., Cassetta L., Presta M., Rusnati M. HIV-1 Tat and heparan sulfate proteoglycan interaction: a novel mechanism of lymphocyte adhesion and migration across the endothelium. Blood 2009, 114:3335-3342.
61. Watson K., Edwards R.J. HIV-1-trans-activating (Tat) protein: both a target and a tool in therapeutic approaches. Biochem. Pharmacol. 1999, 58:1521-1528.
62. Woods A., Oh E.S., Couchman J.R. Syndecan proteoglycans and cell adhesion. Matrix Biol. 1998, 17:477-483.
63. Wright C.M., Felber B.K., Paskalis H., Pavlakis G.N. Expression and characterization of the trans-activator of HTLV-III/LAV virus. Science 1986, 234:988-992.